earnings
confidence high
sentiment neutral
materiality 0.70
PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests
PAVmed Inc.
2026-Q1 EPS reported
-$4.42
revenue$22,000
- GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).
- Cash and equivalents $6.5M at Mar 31, up from $1.5M at Dec 31, 2025.
- Lucid Diagnostics Q1 EsoGuard revenue $1.3M, 3,177 tests processed; raised $17M in public offering, proforma cash $45M.
- Veris Health advancing implantable physiological monitor towards FDA 510(k) submission.
- PAVmed relaunched medical device portfolio including PortIO and Duke-licensed endoscopic imaging.
item 2.02item 7.01item 9.01